fourteen patients with poor-risk acute myelogenous leukaemia ( aml ) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia ( cml ) were treated with 3 days of oral idarubicin ( 25 mg/m2/day ) .
C0023467
acute myelogenous leukaemia
C0020789
idarubicin